Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
暂无分享,去创建一个
T. Imaizumi | S. Yamagishi | T. Matsui | Kazuo Nakamura | So Ueda | Y. Noda | T. Matsui
[1] S. Yamagishi,et al. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. , 2007, Current pharmaceutical design.
[2] T. Niwa,et al. Pyridoxal phosphate prevents progression of diabetic nephropathy. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] Takafumi Yoshida,et al. Atorvastatin Inhibits Advanced Glycation End Products (AGE)-Induced C-Reactive Expression in Hepatoma Cells by Suppressing Reactive Oxygen Species Generation , 2007 .
[4] T. Imaizumi,et al. Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-induced Monocyte Chemoattractant Protein-1 Expression in Mesangial Cells through Downregulation of Receptor for AGEs via Peroxisome Proliferator-activated Receptor-γ Activation , 2007 .
[5] D. Sviridov,et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties , 2007, Diabetologia.
[6] K. Nishiyama,et al. Vitamin B6 suppresses apoptosis of NM-1 bovine endothelial cells induced by homocysteine and copper. , 2007, Biochimica et biophysica acta.
[7] S. Fukuhara,et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study , 2007, Diabetologia.
[8] A. Legrand,et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. , 2007, Metabolism: clinical and experimental.
[9] D. Kass,et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension , 2007, Journal of hypertension.
[10] T. Imaizumi,et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes , 2006, Clinical and Experimental Medicine.
[11] N. Traverso,et al. Effects of valsartan therapy on protein glycoxidation. , 2006, Metabolism: Clinical and Experimental.
[12] H. Hirose,et al. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. , 2006, Diabetes research and clinical practice.
[13] S. Yamagishi,et al. Advanced glycation end-products downregulating intervertebral disc cell production of proteoglycans in vitro. , 2006, Journal of neurosurgery. Spine.
[14] Takafumi Yoshida,et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation , 2006, Diabetologia.
[15] Ann Marie Schmidt,et al. Advanced glycation end products: sparking the development of diabetic vascular injury. , 2006, Circulation.
[16] Y. Tseng,et al. Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes , 2006, European journal of clinical investigation.
[17] S. Yamagishi,et al. Oral Adsorbent AST-120 Decreases Serum Levels of AGEs in Patients with Chronic Renal Failure , 2006, Molecular medicine.
[18] S. Yamagishi,et al. Toxic Advanced Glycation End Products (TAGE) Theory in Alzheimer’s Disease , 2006, American journal of Alzheimer's disease and other dementias.
[19] T. Berl,et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] S. Yamagishi,et al. Atorvastatin and diabetic vascular complications. , 2006, Current pharmaceutical design.
[21] W. Hellstrom,et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. , 2006, The journal of sexual medicine.
[22] M. Davies,et al. Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins , 2006, Diabetologia.
[23] T. Imaizumi,et al. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. , 2006, Current neurovascular research.
[24] B. Zinman,et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.
[25] S. Kato,et al. Advanced Glycation End‐Products Attenuate Human Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, Cartilage, and Bone , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] T. Imaizumi,et al. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.
[27] B. Hudson,et al. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage , 2005, Cellular and Molecular Life Sciences CMLS.
[28] W. Hundley,et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. , 2005, Journal of cardiac failure.
[29] Merlin C. Thomas,et al. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. , 2004, Kidney international. Supplement.
[30] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[31] Merlin C. Thomas,et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. , 2004, Diabetes.
[32] Mark E. Williams,et al. Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy , 2004, American Journal of Nephrology.
[33] Paul J Thornalley. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. , 2003, Archives of biochemistry and biophysics.
[34] P. Beisswenger,et al. Metformin inhibition of glycation processes. , 2003, Diabetes & metabolism.
[35] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[36] J. Baynes,et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. , 2003, Kidney international.
[37] Merlin C. Thomas,et al. A Breaker of Advanced Glycation End Products Attenuates Diabetes‐Induced Myocardial Structural Changes , 2003, Circulation research.
[38] A. Heidland,et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products , 2003, Journal of Human Hypertension.
[39] Masayoshi Takeuchi,et al. Glycation—a sweet tempter for neuronal death , 2003, Brain Research Reviews.
[40] Merlin C. Thomas,et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. , 2002, Diabetes.
[41] M. Nangaku,et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.
[42] K. Tsuda,et al. Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats , 2002, Journal of hypertension.
[43] T. Metz,et al. A Post-Amadori Inhibitor Pyridoxamine Also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates of Carbohydrate and Lipid Degradation* , 2002, The Journal of Biological Chemistry.
[44] D. L. Price,et al. Chelating Activity of Advanced Glycation End-product Inhibitors* , 2001, The Journal of Biological Chemistry.
[45] M. Brownlee. Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.
[46] D. Kass,et al. Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker , 2001, Circulation.
[47] H Terato,et al. Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells. , 2001, Mutation research.
[48] S. Takasawa,et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.
[49] R. Natarajan,et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[50] A. Schmidt,et al. Atherosclerosis and diabetes: The rage connection , 2000, Current atherosclerosis reports.
[51] A. Jenkins,et al. Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.
[52] Paul J Thornalley,et al. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. , 2000, Biochemical pharmacology.
[53] Matthew D. Davis,et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.
[54] M. Lagarde,et al. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. , 1999, Biochemical pharmacology.
[55] A. Heidland,et al. Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan , 1999, Mineral and Electrolyte Metabolism.
[56] Z. Makita,et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.
[57] K. Tatsumi,et al. 2‐Isopropylidenehydrazono‐4‐oxo‐thiazolidin‐5‐ylacetanilide (OPB‐9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage , 1999, FEBS letters.
[58] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[59] M. Huijberts,et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[60] T. Miyazaki,et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. , 1997, Kidney international. Supplement.
[61] Z. Makita,et al. Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation , 1997, Diabetes.
[62] J. Bernhagen,et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo , 1996, Nature.
[63] G. Norton,et al. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. , 1996, Circulation.
[64] S. Grundy,et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[65] R. Bucala,et al. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[66] M. Huijberts,et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. , 1993, The Journal of clinical investigation.
[67] J. Witztum,et al. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[68] V. Monnier,et al. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. , 1991, The Journal of biological chemistry.
[69] J. Baynes,et al. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. , 1991, The Journal of biological chemistry.
[70] A. Cerami,et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.
[71] J. Saumet,et al. Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice. , 2006, Cardiovascular research.
[72] T. Imaizumi,et al. Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention. , 2004, International journal of clinical pharmacology research.
[73] T. Regan,et al. Left ventricular diastolic dysfunction in diabetic or hypertensive subjects: role of collagen alterations. , 2001, Advances in experimental medicine and biology.
[74] G. Jerums,et al. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. , 1998, Atherosclerosis.
[75] R. Bucala,et al. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. , 1992, Advances in pharmacology.